Cargando…
Early, biomarker-guided steroid dosing in COVID-19 Pneumonia: a pilot randomized controlled trial
ClinicalTrials.gov identifier (NCT number): NCT03852537, Registered February 25, 2019.
Autores principales: | Odeyemi, Yewande E., Chalmers, Sarah J., Barreto, Erin F., Jentzer, Jacob C., Gajic, Ognjen, Yadav, Hemang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724733/ https://www.ncbi.nlm.nih.gov/pubmed/34983600 http://dx.doi.org/10.1186/s13054-021-03873-2 |
Ejemplares similares
-
Biomarker-Concordant Steroid Use in Critically Ill Patients with Pneumonia
por: Odeyemi, Yewande E., et al.
Publicado: (2020) -
Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: The role of inflammatory biomarkers
por: Chalmers, Sarah, et al.
Publicado: (2019) -
What factors predispose patients to acute respiratory distress syndrome?
por: Odeyemi, Yewande, et al.
Publicado: (2020) -
Rule-Based Cohort Definitions for Acute Respiratory Distress Syndrome: A Computable Phenotyping Strategy Based on the Berlin Definition
por: Li, Heyi, et al.
Publicado: (2021) -
Respiratory failure in the hematopoietic stem cell transplant recipient
por: Wieruszewski, Patrick M, et al.
Publicado: (2018)